Finance

ą¤øą„‚ą¤šą„€
Q3 2026 ą¤•ą¤®ą¤¾ą¤ˆ ā€¢ 2 ą¤¦ą¤æą¤µą¤øą¤¾ą¤‚ą¤®ą¤§ą„ą¤Æą„‡
ą¤¤ą¤Ŗą¤¶ą„€ą¤² ą¤Ŗą¤¹ą¤¾
HUMA:NASDAQ
Humacyte Inc
$ą„¦.ą„Ŗą„«
+ą„§ą„©.ą„©ą„Ø%
(+ą„¦.ą„¦ą„«ą„©) ą„§ ą¤¦ą¤æ
$ą„¦.ą„Ŗą„«
+ą„¦.ą„«ą„¬% (+ą„¦.ą„¦ą„¦ą„Øą„«)
ą¤®ą¤¾ą¤°ą„ą¤•ą„‡ą¤Ÿą¤šą„ą¤Æą¤¾ ą¤µą„‡ą¤³ą„‡ą¤Øą¤‚ą¤¤ą¤°
ą¤¬ą¤‚ą¤¦: ą„¬ ą¤Øą„‹ą¤µą„ą¤¹ą„‡ą¤‚, ą„Ŗ:ą„¦ą„¦:ą„¦ą„§ PM [GMT]-ą„«  ·   USD
ą¤øą¤°ą„ą¤µ ą¤øą¤æą¤®ą„ą¤¬ą„‰ą¤²
ą¤øą¤æą¤®ą„ą¤¬ą„‰ą¤²ą¤•ą¤æą¤‚ą¤®ą¤¤ą¤¬ą¤¦ą¤²% ą¤¬ą¤¦ą¤²
HUMA ą¤øą¤¾ą¤ ą„€ ą¤Ÿą„‰ą¤Ŗ ą¤‡ą¤Øą¤øą¤¾ą¤‡ą¤Ÿ ą¤œą¤Øą¤°ą„‡ą¤Ÿ ą¤•ą¤°ą¤¤ ą¤†ą¤¹ą„‡...
ą¤‰ą¤˜ą¤”ą¤¾
$ą„¦.ą„Ŗą„§
ą¤‰ą¤šą„ą¤š
$ą„¦.ą„Ŗą„«
ą¤•ą¤®ą„€
$ą„¦.ą„Ŗą„¦
ą¤®ą¤¾ą¤°ą„ą¤•ą„‡ą¤Ÿ ą¤•ą„…ą¤Ŗ
ą„§ą„Ø.ą„©ą„§Ā ą¤•ą„‹ą¤Ÿą„€
ą¤øą¤°ą¤¾ą¤øą¤°ą„€ ą¤‰ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„«ą„¬.ą„¬ą„§Ā ą¤²ą¤¾ą¤–
ą¤‰ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„«ą„§.ą„«ą„®Ā ą¤²ą¤¾ą¤–
ą„«ą„Ø ą¤†ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤‚ą¤¤ą„€ą¤² ą¤‰ą¤šą„ą¤šą¤¾ą¤‚ą¤•
$ą„§.ą„«ą„Ø
ą„«ą„Ø ą¤†ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤‚ą¤¤ą„€ą¤² ą¤Øą„€ą¤šą¤¾ą¤‚ą¤•
$ą„¦.ą„©ą„Ŗ
EPS
-$ą„¦.ą„Ŗą„Æ
ą¤¬ą„€ą¤Ÿą¤¾
ą„Ø.ą„¬ą„Ŗ
ą¤„ą¤•ą¤æą¤¤ ą¤¶ą„‡ą¤…ą¤°
ą„Øą„­.ą„­ą„®Ā ą¤•ą„‹ą¤Ÿą„€
ą¤•ą¤°ą„ą¤®ą¤šą¤¾ą¤±ą„ą¤Æą¤¾ą¤‚ą¤šą„€ ą¤øą¤‚ą¤–ą„ą¤Æą¤¾
ą„§ą„®ą„Ŗ
ą¤‰ą¤˜ą¤”ą¤¾
$ą„¦.ą„Ŗą„§
ą¤‰ą¤šą„ą¤š
$ą„¦.ą„Ŗą„«
ą¤•ą¤®ą„€
$ą„¦.ą„Ŗą„¦
ą¤®ą¤¾ą¤°ą„ą¤•ą„‡ą¤Ÿ ą¤•ą„…ą¤Ŗ
ą„§ą„Ø.ą„©ą„§Ā ą¤•ą„‹ą¤Ÿą„€
ą¤øą¤°ą¤¾ą¤øą¤°ą„€ ą¤‰ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„«ą„¬.ą„¬ą„§Ā ą¤²ą¤¾ą¤–
ą¤‰ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„«ą„§.ą„«ą„®Ā ą¤²ą¤¾ą¤–
ą„«ą„Ø ą¤†ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤‚ą¤¤ą„€ą¤² ą¤‰ą¤šą„ą¤šą¤¾ą¤‚ą¤•
$ą„§.ą„«ą„Ø
ą„«ą„Ø ą¤†ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤‚ą¤¤ą„€ą¤² ą¤Øą„€ą¤šą¤¾ą¤‚ą¤•
$ą„¦.ą„©ą„Ŗ
EPS
-$ą„¦.ą„Ŗą„Æ
ą¤¬ą„€ą¤Ÿą¤¾
ą„Ø.ą„¬ą„Ŗ
ą¤„ą¤•ą¤æą¤¤ ą¤¶ą„‡ą¤…ą¤°
ą„Øą„­.ą„­ą„®Ā ą¤•ą„‹ą¤Ÿą„€
ą¤•ą¤°ą„ą¤®ą¤šą¤¾ą¤±ą„ą¤Æą¤¾ą¤‚ą¤šą„€ ą¤øą¤‚ą¤–ą„ą¤Æą¤¾
ą„§ą„®ą„Ŗ
ą¤¬ą¤¾ą¤¤ą¤®ą„ą¤Æą¤¾ą¤‚ą¤šą„ą¤Æą¤¾ ą¤øą„ą¤Ÿą„‹ą¤°ą„€
ą¤µą„‡ą¤¬ ą¤øą„ą¤°ą„‹ą¤¤ ą¤†ą¤£ą¤æ ą¤¬ą¤¾ą¤¤ą¤®ą„€ ą¤­ą¤¾ą¤—ą„€ą¤¦ą¤¾ą¤°ą¤¾ą¤‚ą¤•ą¤”ą„‚ą¤Ø
Zacks
Zacks
·
ą„Ø ą¤¦ą¤æą¤µą¤øą¤¾ą¤‚ą¤Ŗą„‚ą¤°ą„ą¤µą„€
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
Humacyte Inc ą¤¬ą¤¦ą„ą¤¦ą¤²
CEOą¤²ą„‰ą¤°ą¤¾ ą¤Øą¤æą¤•ą¤²ą¤¾ą¤øą¤Ø
ą¤•ą¤°ą„ą¤®ą¤šą¤¾ą¤°ą„€ą„§ą„®ą„Ŗ
ą¤øą„ą¤„ą¤¾ą¤Ŗą¤Øą¤¾ą„§ ą¤œą¤¾ą¤Øą„‡, ą„Øą„¦ą„¦ą„Ŗ
ą¤®ą„ą¤–ą„ą¤Æą¤¾ą¤²ą¤Æą„‡-
ą¤•ą„ą¤·ą„‡ą¤¤ą„ą¤°Health Care
ą¤‰ą¤¦ą„ą¤Æą„‹ą¤—-
ą¤µą„‡ą¤¬ą¤øą¤¾ą¤‡ą¤Ÿhumacyte.com
ą¤µą¤æą¤¶ą„ą¤²ą„‡ą¤·ą¤•ą¤¾ą¤‚ą¤šą„€ ą¤°ą„‡ą¤Ÿą¤æą¤‚ą¤—
ą¤®ą¤¾ą¤—ą„€ą¤² ą„© ą¤®ą¤¹ą¤æą¤Øą„ą¤Æą¤¾ą¤‚ą¤®ą¤§ą„ą¤Æą„‡ 4 ą¤µą¤æą¤¶ą„ą¤²ą„‡ą¤·ą¤•ą¤¾ą¤‚ą¤Øą„€ HUMA ą¤²ą¤¾ ą¤¦ą¤æą¤²ą„‡ą¤²ą„ą¤Æą¤¾ ą¤øą„ą¤Ÿą„‰ą¤• ą¤°ą„‡ą¤Ÿą¤æą¤‚ą¤—ą¤µą¤° ą¤†ą¤§ą¤¾ą¤°ą¤æą¤¤
ą¤–ą¤°ą„‡ą¤¦ą„€ ą¤•ą¤°ą¤¾
ą¤–ą¤°ą„‡ą¤¦ą„€ ą¤•ą¤°ą¤¾
2
ą¤¹ą„‹ą¤²ą„ą¤” ą¤•ą¤°ą¤¾
2
ą¤µą¤æą¤•ą„ą¤°ą„€ ą¤•ą¤°ą¤¾
0
ą„§ą„Ø ą¤®ą¤¹ą¤æą¤Øą„ą¤Æą¤¾ą¤‚ą¤šą¤¾ ą¤…ą¤‚ą¤¦ą¤¾ą¤œ
ą¤®ą¤¾ą¤—ą„€ą¤² ą„© ą¤®ą¤¹ą¤æą¤Øą„ą¤Æą¤¾ą¤‚ą¤®ą¤§ą„ą¤Æą„‡ 4 ą¤µą„‰ą¤² ą¤øą„ą¤Ÿą„ą¤°ą„€ą¤Ÿ ą¤µą¤æą¤¶ą„ą¤²ą„‡ą¤·ą¤•ą¤¾ą¤‚ą¤Øą„€ HUMA ą¤øą¤¾ą¤ ą„€ ą¤µą¤°ą„ą¤¤ą¤µą¤²ą„‡ą¤²ą„ą¤Æą¤¾ ą„§ą„Ø ą¤®ą¤¹ą¤æą¤Øą„ą¤Æą¤¾ą¤‚ą¤šą„ą¤Æą¤¾ ą¤•ą¤æą¤®ą¤¤ą„€ą¤šą„ą¤Æą¤¾ ą¤²ą¤•ą„ą¤·ą„ą¤Æą¤¾ą¤‚ą¤µą¤° ą¤†ą¤§ą¤¾ą¤°ą¤æą¤¤.
ą¤øą¤°ą„ą¤µą„‹ą¤šą„ą¤š
ą¤øą¤¦ą„ą¤Æ $ą„¦.ą„Ŗą„«
$ą„Ŗ.ą„¦ą„¦ (+ą„­ą„Æą„Ø.ą„Ŗą„¬%)
ą¤øą¤°ą¤¾ą¤øą¤°ą„€
$ą„§.ą„¬ą„Æ (+ą„Øą„­ą„­.ą„¦ą„¬%)
ą¤øą¤°ą„ą¤µą¤¾ą¤¤ ą¤•ą¤®ą„€
$ą„¦.ą„«ą„¦ (+ą„§ą„§.ą„«ą„¬%)
ą¤µą¤æą¤¶ą„ą¤²ą„‡ą¤·ą¤•
ą¤¶ą¤æą¤«ą¤¾ą¤°ą¤ø
ą¤•ą„ƒą¤¤ą„€
ą¤•ą¤æą¤®ą¤¤ą„€ą¤šą„‡ ą¤²ą¤•ą„ą¤·ą„ą¤Æ
ą¤…ą¤‚ą¤¦ą¤¾ą¤œą„‡
ą¤¤ą¤¾ą¤°ą„€ą¤–
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$ą„Ŗ.ą„¦ą„¦
+ą„­ą„Æą„Ø.ą„«%
10/16/2026
Christopher Pasquale
Barclays
Hold
Initiated
$ą„¦.ą„«ą„¦
+ą„§ą„§.ą„¬%
10/07/2026
Matt Miksic
Barclays
Hold
Maintained
$ą„¦.ą„«ą„¦
+ą„§ą„§.ą„¬%
10/07/2026
Josh Jennings
TD Cowen
Buy
Maintained
$ą„§.ą„Øą„«
+ą„§ą„­ą„®.ą„Æ%
08/19/2026
Allison Bratzel
Piper Sandler
Hold
Maintained
$ą„§.ą„¦ą„¦
+ą„§ą„Øą„©.ą„§%
08/17/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$ą„Ø.ą„¦ą„¦
+ą„©ą„Ŗą„¬.ą„Ø%
07/28/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$ą„Ø.ą„¦ą„¦
+ą„©ą„Ŗą„¬.ą„Ø%
06/01/2026
ą¤Ŗą„ą¤¢ą„€ą¤² ą¤•ą„‰ą¤² ą¤Æą„‡ą¤¤ą„ą¤Æą¤¾ ą„Ø ą¤¦ą¤æą¤µą¤øą¤¾ą¤‚ą¤®ą¤§ą„ą¤Æą„‡ ą¤®ą¤§ą„ą¤Æą„‡
ą¤®ą¤‚ą¤—ą¤³, ą„§ą„¦ ą¤Øą„‹ą¤µą„ą¤¹ą„‡ą¤‚, ą„©:ą„¦ą„¦ PM
ą¤†ą¤°ą„ą¤„ą¤æą¤• ą¤•ą¤¾ą¤²ą¤¾ą¤µą¤§ą„€
ą¤¤ą¤æ3 2026
- / -$ą„¦.ą„¦ą„®
ą¤•ą¤®ą¤¾ą¤ˆ / ą¤…ą¤‚ą¤¦ą¤¾ą¤œą„‡ (USD)
- / ą„­.ą„­ą„¦Ā ą¤²ą¤¾ą¤–
ą¤†ą¤°ą„ą¤„ą¤æą¤• ą¤µą¤°ą„ą¤· ą¤¤ą¤æą¤øą¤°ą„€ ą¤¤ą¤æą¤®ą¤¾ą¤¹ą„€ 2026 ą¤•ą¤®ą¤¾ą¤ˆą¤¶ą„€ ą¤øą¤‚ą¤¬ą¤‚ą¤§ą¤æą¤¤ ą¤•ą„‰ą¤²
ą¤•ą¤®ą¤¾ą¤ˆą¤¶ą„€ ą¤øą¤‚ą¤¬ą¤‚ą¤§ą¤æą¤¤ ą¤•ą„‰ą¤²ą¤šą„€ ą¤Ŗą„ą¤°ą¤¤ą„€ą¤•ą„ą¤·ą¤¾ ą¤•ą¤°ą¤¤ ą¤†ą¤¹ą„‡
ą¤ą¤• ą¤¦ą„ƒą¤·ą„ą¤Ÿą¤æą¤•ą„ą¤·ą„‡ą¤Ŗ: ą¤†ą¤—ą¤¾ą¤®ą„€ ą¤•ą¤®ą¤¾ą¤ˆ
ą¤Øą¤µą„€ą¤Øą¤¤ą¤® ą¤¬ą¤¾ą¤¤ą¤®ą„ą¤Æą¤¾ ą¤†ą¤£ą¤æ ą¤…ą¤¹ą¤µą¤¾ą¤² ą¤Æą¤¾ą¤‚ą¤®ą¤§ą„€ą¤² ą¤‡ą¤Øą¤øą¤¾ą¤‡ą¤Ÿ
ą¤®ą¤¾ą¤—ą„€ą¤² ą¤…ą¤¹ą¤µą¤¾ą¤²USD ą¤®ą¤§ą„€ą¤² ą¤øą¤°ą„ą¤µ ą¤®ą„‚ą¤²ą„ą¤Æą„‡
Loading Previous Earnings...
ą¤•ą¤®ą¤¾ą¤ˆ
ą¤Øą¤æą¤µą„ą¤µą¤³ ą¤‰ą¤¤ą„ą¤Ŗą¤Øą„ą¤Ø
USD ą¤®ą¤§ą„€ą¤² ą¤øą¤°ą„ą¤µ ą¤®ą„‚ą¤²ą„ą¤Æą„‡
ą¤øą¤Ŗą„ą¤Ÿą„‡ą¤‚ ą„Øą„¦ą„Øą„«
ą¤”ą¤æą¤øą„‡ą¤‚ ą„Øą„¦ą„Øą„«
ą¤®ą¤¾ą¤°ą„ą¤š ą„Øą„¦ą„Øą„¬
ą¤œą„‚ą¤Ø ą„Øą„¦ą„Øą„¬
ą¤•ą¤®ą¤¾ą¤ˆ
ą„­.ą„«ą„©Ā ą¤²ą¤¾ą¤–
ą„Ŗ.ą„¬ą„­Ā ą¤²ą¤¾ą¤–
ą„Ŗ.ą„Æą„«Ā ą¤²ą¤¾ą¤–
ą„Ŗ.ą„¦ą„¬Ā ą¤²ą¤¾ą¤–
ą¤µą¤æą¤•ą„ą¤°ą„€ ą¤•ą„‡ą¤²ą„‡ą¤²ą„ą¤Æą¤¾ ą¤µą¤øą„ą¤¤ą„‚ą¤‚ą¤šą„‡ ą¤¶ą„ą¤²ą„ą¤•
ą„§.ą„­ą„«Ā ą¤•ą„‹ą¤Ÿą„€
ą„Ø.ą„©ą„­Ā ą¤•ą„‹ą¤Ÿą„€
ą„Ø.ą„¦ą„ÆĀ ą¤•ą„‹ą¤Ÿą„€
ą„§.ą„Æą„ŖĀ ą¤•ą„‹ą¤Ÿą„€
ą¤®ą¤¹ą¤øą„ą¤²ą¤¾ą¤šą„‡ ą¤¶ą„ą¤²ą„ą¤•
ą„§.ą„­ą„«Ā ą¤•ą„‹ą¤Ÿą„€
ą„Ø.ą„©ą„­Ā ą¤•ą„‹ą¤Ÿą„€
ą„Ø.ą„¦ą„ÆĀ ą¤•ą„‹ą¤Ÿą„€
ą„§.ą„Æą„ŖĀ ą¤•ą„‹ą¤Ÿą„€
ą¤øą¤‚ą¤¶ą„‹ą¤§ą¤Ø ą¤†ą¤£ą¤æ ą¤µą¤æą¤•ą¤¾ą¤ø ą¤Æą¤¾ą¤‚ą¤øą¤‚ą¤¬ą¤‚ą¤§ą¤æą¤¤ ą¤–ą¤°ą„ą¤š
-
-
-
-
ą¤øą¤‚ą¤¶ą„‹ą¤§ą¤Ø ą¤†ą¤£ą¤æ ą¤µą¤æą¤•ą¤¾ą¤ø ą¤Æą¤¾ą¤‚ą¤øą¤‚ą¤¬ą¤‚ą¤§ą¤æą¤¤ ą¤ą¤•ą„‚ą¤£ ą¤–ą¤°ą„ą¤š
-
-
-
-
ą¤µą¤æą¤•ą„ą¤°ą„€, ą¤øą¤¾ą¤®ą¤¾ą¤Øą„ą¤Æ ą¤†ą¤£ą¤æ ą¤Ŗą„ą¤°ą¤¶ą¤¾ą¤øą¤•ą„€ą¤Æ ą¤–ą¤°ą„ą¤š
ą„­ą„¬.ą„§ą„¦Ā ą¤²ą¤¾ą¤–
ą„­ą„¬.ą„§ą„¬Ā ą¤²ą¤¾ą¤–
ą„­ą„®.ą„©ą„¦Ā ą¤²ą¤¾ą¤–
ą„®ą„¦.ą„Øą„­Ā ą¤²ą¤¾ą¤–
ą¤•ą¤¾ą¤®ą¤•ą¤¾ą¤œą¤¾ą¤šą¤¾ ą¤–ą¤°ą„ą¤š
ą„­ą„¬.ą„§ą„¦Ā ą¤²ą¤¾ą¤–
ą„­ą„¬.ą„§ą„¬Ā ą¤²ą¤¾ą¤–
ą„­ą„®.ą„©ą„¦Ā ą¤²ą¤¾ą¤–
ą„®ą„¦.ą„Øą„­Ā ą¤²ą¤¾ą¤–
ą¤•ą¤¾ą¤®ą¤•ą¤¾ą¤œą¤¾ą¤šą¤¾ ą¤ą¤•ą„‚ą¤£ ą¤–ą¤°ą„ą¤š
ą„Ø.ą„«ą„§Ā ą¤•ą„‹ą¤Ÿą„€
ą„©.ą„§ą„©Ā ą¤•ą„‹ą¤Ÿą„€
ą„Ø.ą„®ą„­Ā ą¤•ą„‹ą¤Ÿą„€
ą„Ø.ą„­ą„ŖĀ ą¤•ą„‹ą¤Ÿą„€
ą¤•ą¤¾ą¤®ą¤•ą¤¾ą¤œą¤¾ą¤šą„‡ ą¤‰ą¤¤ą„ą¤Ŗą¤Øą„ą¤Ø
-ą„Ø.ą„Ŗą„ŖĀ ą¤•ą„‹ą¤Ÿą„€
-ą„©.ą„¦ą„®Ā ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„®ą„ØĀ ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„­ą„¦Ā ą¤•ą„‹ą¤Ÿą„€
ą¤•ą¤¾ą¤®ą¤•ą¤¾ą¤œą¤¾ą¤šą„‡ ą¤Øą¤øą¤²ą„‡ą¤²ą„‡ ą¤‡ą¤¤ą¤° ą¤‰ą¤¤ą„ą¤Ŗą¤Øą„ą¤Ø
ą„Ŗą„¦.ą„¦ą„ÆĀ ą¤²ą¤¾ą¤–
ą„Ø.ą„¦ą„¬Ā ą¤•ą„‹ą¤Ÿą„€
ą„®ą„«.ą„Øą„«Ā ą¤²ą¤¾ą¤–
-ą„«ą„§.ą„«ą„«Ā ą¤²ą¤¾ą¤–
ą¤…ą¤øą¤¾ą¤®ą¤¾ą¤Øą„ą¤Æ ą¤†ą¤Æą¤Ÿą¤®ą¤šą„ą¤Æą¤¾ ą¤øą¤®ą¤¾ą¤µą„‡ą¤¶ą¤¾ą¤øą¤¹ EBT
-ą„§.ą„­ą„«Ā ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„Ŗą„®Ā ą¤•ą„‹ą¤Ÿą„€
-ą„§.ą„­ą„¬Ā ą¤•ą„‹ą¤Ÿą„€
-ą„©.ą„¬ą„®Ā ą¤•ą„‹ą¤Ÿą„€
ą¤…ą¤øą¤¾ą¤®ą¤¾ą¤Øą„ą¤Æ ą¤†ą¤Æą¤Ÿą¤® ą¤µą¤—ą¤³ą„‚ą¤Ø EBT
-ą„Ø.ą„Øą„ŖĀ ą¤•ą„‹ą¤Ÿą„€
-ą„§.ą„Øą„ÆĀ ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„§ą„­Ā ą¤•ą„‹ą¤Ÿą„€
-ą„©.ą„Ŗą„§Ā ą¤•ą„‹ą¤Ÿą„€
ą¤†ą¤Æą¤•ą¤°ą¤¾ą¤µą¤°ą„€ą¤² ą¤–ą¤°ą„ą¤š
-
-
-
-
ą¤Ŗą„ą¤°ą¤­ą¤¾ą¤µą„€ ą¤•ą¤° ą¤¦ą¤°
-
-
-
-
ą¤•ą¤¾ą¤®ą¤•ą¤¾ą¤œą¤¾ą¤šą¤¾ ą¤‡ą¤¤ą¤° ą¤–ą¤°ą„ą¤š
-
-
-
-
ą¤Øą¤æą¤µą„ą¤µą¤³ ą¤‰ą¤¤ą„ą¤Ŗą¤Øą„ą¤Ø
-ą„§.ą„­ą„«Ā ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„Ŗą„®Ā ą¤•ą„‹ą¤Ÿą„€
-ą„§.ą„­ą„¬Ā ą¤•ą„‹ą¤Ÿą„€
-ą„©.ą„¬ą„®Ā ą¤•ą„‹ą¤Ÿą„€
ą¤Øą¤æą¤µą„ą¤µą¤³ ą¤Øą¤«ą„ą¤Æą¤¾ą¤šą„‡ ą¤®ą¤¾ą¤°ą„ą¤œą¤æą¤Ø
-ą„Ø,ą„©ą„Øą„«.ą„©ą„­%
-ą„«,ą„©ą„§ą„§.ą„©ą„«%
-ą„©,ą„«ą„«ą„Æ.ą„©ą„Æ%
-ą„Æ,ą„¦ą„¬ą„Ŗ.ą„«ą„©%
ą¤Ŗą„ą¤°ą¤¤ą¤æ ą¤¶ą„‡ą¤…ą¤° ą¤•ą¤®ą¤¾ą¤ˆ
-ą„¦.ą„§ą„§
-ą„¦.ą„§ą„©
-ą„¦.ą„¦ą„Æ
-ą„¦.ą„§ą„¬
ą¤µą„ą¤Æą¤¾ą¤œ ą¤†ą¤£ą¤æ ą¤—ą„ą¤‚ą¤¤ą¤µą¤£ą„‚ą¤• ą¤Æą¤¾ą¤‚ą¤®ą¤§ą„‚ą¤Ø ą¤®ą¤æą¤³ą¤£ą¤¾ą¤°ą„‡ ą¤‰ą¤¤ą„ą¤Ŗą¤Øą„ą¤Ø
ą„«.ą„Æą„¦Ā ą¤²ą¤¾ą¤–
ą„«.ą„¦ą„©Ā ą¤²ą¤¾ą¤–
ą„©.ą„©ą„¦Ā ą¤²ą¤¾ą¤–
ą„©.ą„®ą„®Ā ą¤²ą¤¾ą¤–
ą¤µą„ą¤Æą¤¾ą¤œą¤¾ą¤šą¤¾ ą¤–ą¤°ą„ą¤š
-ą„Øą„¬.ą„§ą„ØĀ ą¤²ą¤¾ą¤–
-ą„©ą„¦.ą„Æą„©Ā ą¤²ą¤¾ą¤–
-ą„Øą„Ø.ą„­ą„§Ā ą¤²ą¤¾ą¤–
-ą„Øą„©.ą„Øą„§Ā ą¤²ą¤¾ą¤–
ą¤Øą¤æą¤µą„ą¤µą¤³ ą¤µą„ą¤Æą¤¾ą¤œą¤¾ą¤šą¤¾ ą¤–ą¤°ą„ą¤š
-ą„Øą„¦.ą„Øą„ØĀ ą¤²ą¤¾ą¤–
-ą„Øą„«.ą„Æą„¦Ā ą¤²ą¤¾ą¤–
-ą„§ą„Æ.ą„Ŗą„§Ā ą¤²ą¤¾ą¤–
-ą„§ą„Æ.ą„©ą„©Ā ą¤²ą¤¾ą¤–
ą¤˜ą¤øą¤¾ą¤°ą¤¾ ą¤†ą¤£ą¤æ ą¤Ŗą¤°ą¤æą¤¶ą„‹ą¤§ą¤Ø ą¤Æą¤¾ą¤‚ą¤øą¤‚ą¤¬ą¤‚ą¤§ą¤æą¤¤ ą¤¶ą„ą¤²ą„ą¤•ą„‡
-
-
-
-
EBITDA
-ą„Ø.ą„Øą„«Ā ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„Æą„¦Ā ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„¬ą„ŖĀ ą¤•ą„‹ą¤Ÿą„€
-ą„Ø.ą„«ą„ØĀ ą¤•ą„‹ą¤Ÿą„€
ą¤®ą¤¾ą¤²ą¤®ą¤¤ą„ą¤¤ą¤¾ ą¤µą¤æą¤•ą„‚ą¤Ø ą¤ą¤¾ą¤²ą„‡ą¤²ą¤¾ ą¤Øą¤«ą¤¾ ą¤•ą¤æą¤‚ą¤µą¤¾ ą¤¤ą„‹ą¤Ÿą¤¾
-
ą„«.ą„¦ą„¦Ā ą¤¹
-
-
ą¤…ą¤‚ą¤¤ą¤°ą„ą¤—ą¤¤ ą¤µą„ą¤Æą¤µą¤¹ą¤¾ą¤°
ą¤…ą¤‚ą¤¤ą¤°ą„ą¤—ą¤¤ ą¤µą„ą¤Æą¤•ą„ą¤¤ą„€ą¤‚ą¤šą„ą¤Æą¤¾ ą¤µą„ą¤Æą¤µą¤¹ą¤¾ą¤°ą¤¾ą¤‚ą¤šą¤¾ ą¤”ą„‡ą¤Ÿą¤¾ ą¤¤ą„ƒą¤¤ą„€ą¤Æ ą¤Ŗą¤•ą„ą¤· ą¤øą„ą¤°ą„‹ą¤¤ą¤¾ą¤‚ą¤•ą¤”ą„‚ą¤Ø ą¤®ą¤æą¤³ą¤µą¤²ą¤¾ ą¤œą¤¾ą¤¤ą„‹. ą¤…ą¤§ą¤æą¤• ą¤œą¤¾ą¤£ą„‚ą¤Ø ą¤˜ą„ą¤Æą¤¾
ą¤…ą¤‚ą¤¤ą¤°ą„ą¤—ą¤¤ ą¤µą„ą¤Æą¤•ą„ą¤¤ą„€
ą¤øą„ą¤„ą¤æą¤¤ą„€
ą¤Ŗą„ą¤°ą¤•ą¤¾ą¤°
ą¤¤ą¤¾ą¤°ą„€ą¤–
ą¤¶ą„‡ą¤…ą¤°
ą¤°ą¤•ą„ą¤•ą¤®
ą¤Ŗą„‡ą¤œ 1
ą¤†ą¤—ą¤¾ą¤®ą„€ ą¤‡ą¤µą„ą¤¹ą„‡ą¤‚ą¤Ÿ
AI ą¤†ą¤¶ą¤Æą¤¾ą¤®ą¤§ą„ą¤Æą„‡ ą¤šą„ą¤•ą¤¾ ą¤…ą¤øą„‚ ą¤¶ą¤•ą¤¤ą¤¾ą¤¤. ą¤…ą¤§ą¤æą¤• ą¤œą¤¾ą¤£ą„‚ą¤Ø ą¤˜ą„ą¤Æą¤¾
ą¤®ą¤¦ą¤¤ą¤«ą„€ą¤”ą¤¬ą„…ą¤• ą¤Ŗą¤¾ą¤ ą¤µą¤¾ą¤—ą„‹ą¤Ŗą¤Øą„€ą¤Æą¤¤ą¤¾ą¤…ą¤Ÿą„€ą¤”ą¤æą¤øą„ą¤•ą„ą¤²ą„‡ą¤®ą¤°
Google Apps